Tetroxoprim

Last updated

Tetroxoprim
Tetroxoprim.svg
Clinical data
ATC code
Identifiers
  • 5-[3,5-Dimethoxy-4-(2-methoxyethoxy)benzyl]pyrimidine-2,4-diamine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.053.427 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C16H22N4O4
Molar mass 334.376 g·mol−1
3D model (JSmol)
  • COCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC
  • InChI=1S/C16H22N4O4/c1-21-4-5-24-14-12(22-2)7-10(8-13(14)23-3)6-11-9-19-16(18)20-15(11)17/h7-9H,4-6H2,1-3H3,(H4,17,18,19,20) X mark.svgN
  • Key:WSWJIZXMAUYHOE-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Tetroxoprim (INN) is a derivative of trimethoprim. It was first described in 1979. [1]

Tetroxoprim is used often in combination with sulfadiazine (co-tetroxazine) for treating bacterial infections, [2] [3] with brand names including Biroxin and Tibirox.

References

  1. ↑ Aschhoff HS, Vergin H (November 1979). "Tetroxoprim—a new inhibitor of bacterial dihydrofolate reductase". J Antimicrob Chemother. 5 (B): 19–25. doi:10.1093/jac/5.supplement_b.19. PMID   43863.
  2. ↑ Grimm H (1979). "In vitro bacteriological investigations with tetroxoprim-sulphadiazine-correlation between inhibition zone diameter and minimum inhibitory concentration". Journal of Antimicrobial Chemotherapy. 5: 37–44. doi:10.1093/jac/5.Supplement_B.37.
  3. ↑ Alkaysi H, Salem M, Gharaibeh A, Gharaibeh K, Badwan A (1992). "Bioequivalency studies on tablet formulation of tetroxoprim and sulphadiazine". Journal of Clinical Pharmacy and Therapeutics. 17: 97–99. doi:10.1111/j.1365-2710.1992.tb01274.x.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.